393 related articles for article (PubMed ID: 30171203)
1. Rheumatic immune-related adverse events from cancer immunotherapy.
Calabrese LH; Calabrese C; Cappelli LC
Nat Rev Rheumatol; 2018 Oct; 14(10):569-579. PubMed ID: 30171203
[TBL] [Abstract][Full Text] [Related]
2. Rheumatic complications in cancer patients treated with immune checkpoint inhibitors.
Lee KA; Kim HR; Yoon SY
Korean J Intern Med; 2019 Nov; 34(6):1197-1209. PubMed ID: 31014065
[TBL] [Abstract][Full Text] [Related]
3. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
Leipe J; Mariette X
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?
Gediz F; Kobak S
Curr Rheumatol Rev; 2019; 15(3):201-208. PubMed ID: 30659547
[TBL] [Abstract][Full Text] [Related]
5. [Rheumatological complications of immune checkpoint inhibitor therapy].
Lazarou I; Fernandez E
Rev Med Suisse; 2020 Mar; 16(685):504-507. PubMed ID: 32167253
[TBL] [Abstract][Full Text] [Related]
6. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
Steven NM; Fisher BA
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079
[TBL] [Abstract][Full Text] [Related]
7. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
Narváez J; Juarez-López P; LLuch J; Narváez JA; Palmero R; García Del Muro X; Nolla JM; Domingo-Domenech E
Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042
[TBL] [Abstract][Full Text] [Related]
8. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
[TBL] [Abstract][Full Text] [Related]
9. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer.
Sebastiani GD; Scirocco C; Galeazzi M
Autoimmun Rev; 2019 Aug; 18(8):805-813. PubMed ID: 31176871
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists.
Pacholczak-Madej R; Kosałka-Węgiel J; Kuszmiersz P; Mituś JW; Püsküllüoğlu M; Grela-Wojewoda A; Korkosz M; Bazan-Socha S
Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981837
[TBL] [Abstract][Full Text] [Related]
11. [Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors].
Zhou J; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhang W; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):671-675. PubMed ID: 31650952
[TBL] [Abstract][Full Text] [Related]
12. Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors.
Cano-Cruz LG; Barrera-Vargas A; Mateos-Soria A; Soto-Perez-de-Celis E; Merayo-Chalico J
Arch Med Res; 2022 Feb; 53(2):113-121. PubMed ID: 34649738
[TBL] [Abstract][Full Text] [Related]
13. The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy.
Calabrese LH; Calabrese C
Curr Opin Rheumatol; 2020 Mar; 32(2):175-183. PubMed ID: 31922970
[TBL] [Abstract][Full Text] [Related]
14. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
Kostine M; Rouxel L; Barnetche T; Veillon R; Martin F; Dutriaux C; Dousset L; Pham-Ledard A; Prey S; Beylot-Barry M; Daste A; Gross-Goupil M; Lallier J; Ravaud A; Forcade E; Bannwarth B; Truchetet ME; Richez C; Mehsen N; Schaeverbeke T;
Ann Rheum Dis; 2018 Mar; 77(3):393-398. PubMed ID: 29146737
[TBL] [Abstract][Full Text] [Related]
15. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
[TBL] [Abstract][Full Text] [Related]
16. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
Cappelli LC; Bingham CO
Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
[TBL] [Abstract][Full Text] [Related]
17. [Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition].
Benesova K; Leipe J
Z Rheumatol; 2020 Aug; 79(6):545-553. PubMed ID: 32613268
[TBL] [Abstract][Full Text] [Related]
18. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity.
Calabrese C; Kirchner E; Kontzias A; Velcheti V; Calabrese LH
RMD Open; 2017; 3(1):e000412. PubMed ID: 28405474
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
Kostine M; Truchetet ME; Schaeverbeke T
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
[TBL] [Abstract][Full Text] [Related]
20. Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients.
Richter MD; Crowson C; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U
Arthritis Rheumatol; 2019 Mar; 71(3):468-475. PubMed ID: 30281202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
